% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Galldiks:829453,
      author       = {Galldiks, Norbert and Langen, Karl-Josef},
      title        = {{A}mino acid {PET} in neuro-oncology: applications in the
                      clinic},
      journal      = {Expert review of anticancer therapy},
      volume       = {17},
      number       = {5},
      issn         = {1744-8328},
      address      = {Abingdon, Oxon},
      publisher    = {Taylor $\&$ Francis},
      reportid     = {FZJ-2017-03152},
      pages        = {395-397},
      year         = {2017},
      abstract     = {For more than three decades, radiolabeled amino acids have
                      been used in the field of neuro-oncology. The most
                      experience for this class of positron emission tomography
                      (PET) tracers has been gained with 11C-methyl-l-methionine
                      (MET). MET is labeled with the positron-emitting isotope
                      carbon-11, which has a short half-life of 20 min. Thus, the
                      use of MET is restricted to PET centers with an on-site
                      cyclotron unit. This prompted the development of amino acid
                      tracers labeled with positron emitters that have longer
                      half-lives. More recently, O-(2-[18F]fluoroethyl)-l-tyrosine
                      (FET) was developed and is a 18F-labeled amino acid tracer
                      with a half-life of 110 min, resulting in a higher
                      practicability compared to MET. The use of FET has grown
                      rapidly in recent years, especially in Western Europe, and
                      has led to a replacement of MET by the more convenient FET.
                      The improved availability has led to several thousand FET
                      PET scans being performed in some centers. Furthermore,
                      clinical results with PET using FET and MET seem to be
                      comparable [1 Grosu AL, Astner ST, Riedel E, et al. An
                      interindividual comparison of O-(2-
                      [(18)F]fluoroethyl)-L-tyrosine (FET)- and
                      L-[methyl-(11)C]methionine (MET)-PET in patients with brain
                      gliomas and metastases. Int J Radiat Oncol Biol Phys.
                      2011;81(4):1049–1058.[CrossRef], [PubMed], [Web of Science
                      ®], [Google Scholar]]. The 18F-labeled amino acid analogue
                      3,4-dihydroxy-6-[18F]-fluoro-l-phenylalanine (FDOPA) –
                      primarily developed to evaluate dopamine synthesis in
                      patients with movement disorders – is also increasingly
                      being used for brain tumor imaging [2 Herrmann K, Czernin J,
                      Cloughesy T, et al. Comparison of visual and
                      semiquantitative analysis of 18F-FDOPA-PET/CT for recurrence
                      detection in glioblastoma patients. Neuro Oncol.
                      2014;16(4):603–609.[CrossRef], [PubMed], [Web of Science
                      ®], [Google Scholar]]. However, in the USA, the standard
                      tracer for tumor imaging 18F-2-fluoro-2-deoxy-d-glucose
                      (FDG) PET is still frequently used in brain tumor patients,
                      although the evaluation of brain tumors using FDG is
                      difficult because levels of glucose metabolism in healthy
                      brain parenchyma are usually high. This leads to a poor
                      tumor-to-background contrast compared with amino acid
                      tracers [3 Albert NL, Weller M, Suchorska B, et al. Response
                      assessment in neuro-oncology working group and European
                      Association for Neuro-Oncology recommendations for the
                      clinical use of PET imaging in gliomas. Neuro Oncol.
                      2016;18(9):1199–1208.[CrossRef], [PubMed], [Web of Science
                      ®], [Google Scholar]].},
      cin          = {INM-3 / INM-4 / JARA-BRAIN},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-3-20090406 / I:(DE-Juel1)INM-4-20090406 /
                      $I:(DE-82)080010_20140620$},
      pnm          = {573 - Neuroimaging (POF3-573)},
      pid          = {G:(DE-HGF)POF3-573},
      typ          = {PUB:(DE-HGF)16},
      UT           = {WOS:000399904100001},
      doi          = {10.1080/14737140.2017.1302799},
      url          = {https://juser.fz-juelich.de/record/829453},
}